Entera Bio (ENTX) Proxy Filing summary

Executive summary

• Annual shareholder meeting scheduled for July 16, 2025, in Jerusalem, Israel.

• Shareholders are encouraged to review proxy materials online and vote electronically, by phone, or in person.

Voting matters and shareholder proposals

• Election of Ms. Haya Taitel as a Class II director until the 2028 annual meeting.

• Ratification and approval of revised compensation terms for CEO, Chief of R&D, and CFO.

• Approval of amended and restated compensation policy for directors and officers.

• Advisory, non-binding vote on executive compensation.

• Ratification of Kesselman & Kesselman (PwC) as independent auditors for fiscal year ending December 31, 2025, with authorization for the Board or Audit Committee to set auditor compensation.

Board of directors and corporate governance

• Board recommends a vote in favor of all proposals presented.